Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment
By Ben Glickman
Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
The pharmaceutical company said that Imdelltra, an immunotherapy, was approved by the U.S. Food and Drug Administration for treating adults with extensive-stage small-cell lung cancer.
The indication is specifically for cases with progression on or after platinum-based chemotherapy.
Amgen's treatment received accelerated approval, meaning it was approved based on a surrogate endpoint in a trial.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 16, 2024 19:21 ET (23:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations